Profile: Myriad Genetics Inc (MYGN.O)
28 Apr 2017
Myriad Genetics, Inc. (Myriad), incorporated on November 6, 1992, is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology.
The Company has a diagnostic pipeline across the disease spectrum, including clinical tests in areas of unmet medical need, such as nephrology, autoimmune diseases, diabetes and neuropsychiatry. Its molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual's risk for developing disease later in life, accurately diagnose disease, determine a patient's likelihood of responding to a particular drug, or assess a patient's risk of disease progression and disease recurrence. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx, BRACAnalysis, BART, COLARIS, COLARIS AP, Vectra DA, Prolaris, EndoPredict, myPath Melanoma, myChoice HRD and myPlan Lung Cancer. The Company, through Myriad RBM, provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology.
The Company's myRisk Hereditary Cancer is a deoxyribonucleic acid (DNA) sequencing test for assessing the risks for hereditary cancers. It includes approximately 30-gene panel that helps to determine a patient's risk by evaluating a number of hereditary cancer syndromes, with focus on over eight primary cancer sites. It is designed to determine a patient's hereditary cancer risk for breast cancer, ovarian cancer, colon cancer, uterine cancer, melanoma, pancreatic cancer, prostate cancer and gastric cancer. BRACAnalysis CDx is a DNA sequencing test for use as a companion diagnostic with the poly (Adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor Lynparza (olaparib) indicated for use in identifying ovarian cancer patients with deleterious or suspected deleterious germline Breast Cancer susceptibility gene (BRCA) variants eligible for treatment with Lynparza. BRACAnalysis test is an analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BART test is focused on detecting genomic rearrangements in the genes involved in hereditary breast and ovarian cancer patients. COLARIS is a genetic test that assesses a person's risk of developing hereditary colorectal cancer and a woman's risk of developing hereditary uterine (endometrial) cancer.
COLARIS AP detects mutations in the Adenomatous polyposis coli (APC) and Myosin heavy chains (MYH) genes, which cause adenomatous polyposis colon cancer syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP) and MYH-associated polyposis (MAP). Vectra DA test is a multi-biomarker blood test validated to measure rheumatoid arthritis (RA) disease activity. Prolaris test is a gene expression assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be monitored through active surveillance, or an aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy.
The EndoPredict test is a ribonucleic acid (RNA) expression test used to determine which women with breast cancer would benefit from chemotherapy. It predicts the likelihood of metastases to help guide treatment decisions for chemotherapy and extended anti-hormonal therapy. myPath Melanoma test is a gene expression based profile that is performed on biopsy tissue for the purpose of aiding a dermatopathologist in the diagnosis of melanoma. myChoice HRD test is a homologous recombination deficiency test to detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs, such as platinum drugs. myPlan Lung Cancer test is a gene expression based profile that may aid a physician in making a determination as to the aggressiveness of a patient's lung cancer and based upon this determination guide patient therapy.
Myriad Genetics Inc
320 S Wakara Way
SALT LAKE CITY UT 84108-1214
Company Web Links
- BRIEF-Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test
- BRIEF-Myriad Genetics, Beigene sign agreement
- BRIEF-Myriad Genetics launches the endopredict test in U.S for patients with breast cancer
- BRIEF-D. E. Shaw & CO reports 5 pct passive stake in Myriad Genetics -SEC filing
- BRIEF-Myriad Genetics director Henderson buys 6,000 shares of co's common stock on Feb 22-23